SavedAdd your journal

Journals / Online Türk Sağlık Bilimleri Dergisi / 2022 / Cilt: 7 - Sayı: 2

The Effect of EGFR, P16 and Ki67 Expression on Prognosis in Head and Neck Squamous Cell Carcinoma

Baş-Boyun Skuamöz Hücreli Karsinomlarında EGFR, P16 ve Ki67 Ekspresyonunun Prognoza Etkisi

Sevil KARABAĞ
Ayşegül İSAL ARSLAN
Tolga ERSÖZLÜ
Pages
196–201
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the study, it was aimed to investigate the association between EGFR, p16 and ki67 expression and survival in patients with head and neck squamous cell carcinoma (SCC).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: HPV and EGFR expression status may be utilized as an independent prognostic factor owing to the different clinical and demographic characteristics head and neck cancers.
📊
Key Findings & Data:Objective: HPV and EGFR expression status may be utilized as an independent prognostic factor owing to the different clinical and demographic characteristics head and neck cancers.
💡
Conclusion & Impact:In the study, it was aimed to investigate the association between EGFR, p16 and ki67 expression and survival in patients with head and neck squamous cell carcinoma (SCC).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:baş&boyun skuamöz hücreli karsinom · EGFR · p16

Abstract

Objective: HPV and EGFR expression status may be utilized as an independent prognostic factor owing to the different clinical and demographic characteristics head and neck cancers. In the study, it was aimed to investigate the association between EGFR, p16 and ki67 expression and survival in patients with head and neck squamous cell carcinoma (SCC).

Özet

Amaç: EGFR ve HPV pozitif baş-boyun kanserlerinin, negatif olanlara kıyasla oldukça farklı klinik ve demografik özelliklerinden dolayı HPV ve EGFR ekspresyon durumu bağımsız prognostik faktör olarak kullanılabilir. Bu çalışmanın amacı baş-boyun skuamöz hücreli karsinom vakalarında EGFR, p16 ve ki67 ekspresyonlarının yaşam süresi ile ilişkisini saptamaktır.

🔖

Cite This Article

KARABAĞ, S., ARSLAN, A. İ., ERSÖZLÜ, T. (2022). The Effect of EGFR, P16 and Ki67 Expression on Prognosis in Head and Neck Squamous Cell Carcinoma. Online Türk Sağlık Bilimleri Dergisi, Cilt: 7 - Sayı: 2, 196–201. https://ajindex.com/articles/419563

References (12)

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
  2. Argyris PP, Slama Z, Malz C, et al. Intracellular calprotectin (S100A8/A9) controls epithelial differentiation and caspase-mediated cleavage of EGFR in head and neck squamous cell carcinoma. Oral Oncology. 2019;95:1-10.
  3. Sivasithamparam J, Visk CA, Cohen EE, King AC. Modifiable risk behaviors in patients with head and neck cancer. Cancer. 2013;119:2419-2426.
  4. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2016;66:271-289.
  5. Maxwell SA, Sacks PG, Gutterman JU, Gallick GE. Epidermal growth factor receptor protein-tyrosine kinase activity in human cell lines established from squamous carcinomas of the head and neck. Cancer Res. 1989;49(5):1130-1137.
  6. Bossi P, Resteghini C, Paielli N, Licitra L, Pilotti S, Perrone F. Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. Oncotarget. 2016;7(45):74362-74379.
  7. Almadori G, Cadoni G, Cattani P, et al. Human papillomavirus infection and epidermal growth factor receptor expression in primary laryngeal squamous cell carcinoma. Clin Cancer Res. 2001;7:3988-3993.
  8. Vermorken JB, Mesia R, Rivera F, et al. Platinumbased chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116-1127. Mesía R, Henke M, Fortin A, et al. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015;16:208-220.
  9. Giralt J, Trigo J, Nuyts S, et al. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015;16:221-232.
  10. Gioacchini FM, Alicandri‑Ciufelli M, Magliulo G, Rubini C, Presutti L, Re M. The clinical relevance of Ki‑67 expression in laryngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2015;272:1569-1576.
  11. Maebayashi T, Ishibashi N, Aizawa T, et al. Roles of Ki-67 and p16 as biomarkers for unknown primary head and neck squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology. 2019;276:1221-1229.
  12. Kontic M, Colovic Z, Paladin I, Mirko Gabelica, Baric A, Pesutic-Pisac V. Association between EGFR expression and clinical outcome of laryngeal HPV squamous c